System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 54 citations

PubMed: 35243742 DOI: 10.1111/jth.15689

P- and E- selectin in venous thrombosis and non-venous pathologies.

J Thromb Haemost 20(5):1056-1066

Authors: Megan Purdy, Andrea Obi, Daniel Myers, Thomas Wakefield

Affiliations

  • University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Unit for Laboratory Animal Medicine and Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA.

Abstract

Venous thromboembolism is a very common and costly health problem worldwide. Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding, and none prevent the development of post thrombotic syndrome after deep vein thrombosis or chronic thromboembolic pulmonary hypertension after pulmonary embolism. For these reasons, alternate forms of therapy with improved efficacy and decreased bleeding are needed. Selectins are a family (P-selectin, E-selectin, L-selectin) of glycoproteins that facilitate and augment thrombosis, modulating neutrophil, monocyte, and platelet activity. P- and E-selectin have been investigated as potential biomarkers for thrombosis. Inhibition of P-selectin and E-selectin decrease thrombosis and vein wall fibrosis, with no increase in bleeding. Selectin inhibition is a promising avenue of future study as either a stand-alone treatment for VTE or as an adjunct to standard anticoagulation therapies.

MeSH

Embolism, L-Selectin, Hemorrhage, Venous Thrombosis, Pathology, E-Selectin, Pulmonary Embolism, Therapeutics, Venous Thromboembolism, Thrombosis, Veins, Selectins

Cited by